Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and recombinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and recombinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-1079; constructs and recombinant host cells incorporating the genes; the nGPCR-1079 polypeptides encoded by the gene; antibodies to the nGPCR-1079 polypeptides; and methods of making and using all of the foregoing.

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-2067; constructs and recombinant host cells incorporating the genes; the nGPCR-2067 polypeptides encoded by the gene; antibodies to the nGPCR-2067 polypeptides; and methods of making and using all of the foregoing.

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-2037; constructs and recombinant host cells incorporating the genes; the nGPCR-2037 polypeptides encoded by the gene; antibodies to the nGPCR-2037 polypeptides; and methods of making and using all of the foregoing.

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and recombinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-1025; constructs and recombinant host cells incorporating the genes; the nGPCR-1025 polypeptides encoded by the gene; antibodies to the nGPCR-1025 polypeptides; and methods of making and using all of the foregoing.

Abstract: An apparatus for transporting pipette tips is provided which comprises a vacuum manifold and one or more air conduits. The vacuum manifold internally defines a vacuum chamber, and has a wall which defines one or more apertures. The vacuum manifold is adapted for use in conjunction with a vacuum source. An air conduit is fixed to each of the one or more apertures defined by the wall of the vacuum manifold. Each air conduit defines an air channel, and is sized such that it can be inserted through a proximal opening defined by the head of one of the pipette tips without contacting the inner surface of the head of the pipette tip. The air channel of each air conduit is larger than a distal opening defined by the body of the pipette tip, such that when each air conduit is inserted through the proximal opening of one of the pipette tips and a vacuum source is used in conjunction with the vacuum manifold to create a vacuum in the vacuum chamber, the pipette tips are held in engagement with the vacuum manifold.

Abstract: The invention relates to antibodies which is capable of binding the monocyte chemoattractant protein 1 (MCP-1) receptor CCR2, especially those which are capable of acting either as an antagonist or agonist. The claimed antobodies can be used for in vitro and/or in vivo diagnostic, for screening and detection of tissues and classes of cells expressing the MCP-1 receptor, for screening for new drugs and for therapeutic use. The invention also relates to a preparation comprising the claimed antibody and a micro-organism or cell-line capable of producing the claimed antibody.

Abstract: The invention relates to a method for treatment of obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus by administering a drug capable of modulating the regulation of UCP-2, the use of a drug capable of modulating the regulation of UCP-2 for the production of drug for treatment of obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus and pharmaceutical composition comprising a pharmaceutically effective amount of such a drug. The invention is also related to methods for screening for potential drugs against obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus and the use of cDNA probe for determination of upregulation of UCP-2 for potential drugs against obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus.

Abstract: Substantially pure dimers of Apolipoprotein Al-Milano (Al-M/APO Al-M) isolated and characterized from plasma are provided. Pharmaceutical compositions comprising the Apo Al-M/Apo Al-M are also provided. Apolipoprotein Al-M dimer can be produced in a recombinant Escherichia coli system or collected from plasma from Apolipoprotein Al-Milano carriers. Atherosclerosis and cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used for preventing thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.

Abstract: A DNA sequence coding for a biologically active recombinant human factor VIII derivative, comprising a first DNA segment coding for the amino acids 1 through 740 of human factor VIII and a second DNA segment coding for the amino acids 1649 through 2332 of human factor VIII, said segments being interconnected by a linker DNA segment coding for a linker peptide of at least 3 amino acid residues and up to about 10 amino acid residues which are selected from lysine and arginine; recombinant expression vector comprising such DNA sequence; host cells of animal origin transformed with such recombinant expression vector; a process for the manufacture of recombinant human factor VIII derivative; and human factor VIII derivative containing the heavy chain and the light chain linked by metal ion bond.

Abstract: A monoclonal antibody that reacts with the CA-242 antigen is provided. The antibody can be obtained by culturing the hybridoma cell line C242:II with the ECACC identification number 90012601, or an artificial or spontaneous mutant thereof. Cell lines producing the antibody are also provided. The antibody is useful for therapeutic and diagnostic purposes.

Abstract: A multiple intensity lamp controller and lighting system utilizing a multiple filament lamp having a primary filament and a secondary filament coupled in series with each other and with a power source and having a variable impedance coupled across the secondary filament. The intensity of the multiple filament lamp is made comparatively bright when the value of the variable impedance is made comparatively low. Conversely, the intensity of the multiple filament lamp is made comparatively dim when the value of the variable impedance is made comparatively high.

Abstract: A solid-state programmable control circuit provides multiple time selected application of A.C. power to one or more utilization circuits or devices. The control circuit uses a crystal controlled time base generator which is synchronized to commercial A.C. power. Stand-by battery power is provided to maintain timing when A.C. power is lost. A time display plug-in module is used with the circuit for setting the time for the control circuit. Programming can be done at a point remote from the control circuit.